Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
September 24, 2024 08:45 ET
|
Curium
Curium opens new Netherlands facility for Lu-177 production, ensuring a steady supply of this breakthrough cancer therapy isotope for over 100,000 patients
Phase III Clinical Trial Published in New England Journal Of Medicine Identifies New Standards for Prevention of Graft Versus Host Disease Following Transplant
June 22, 2023 11:00 ET
|
Be The Match
MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- Results of a Phase III randomized clinical trial published in the New England Journal of Medicine indicates that a new strategy for prevention of graft...
Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
March 23, 2023 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapy drugs that provide a better...
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
December 20, 2022 08:50 ET
|
Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumors HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) --...
Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
December 19, 2022 10:24 ET
|
Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsHOUSTON, Texas, Dec. 19, 2022 (GLOBE NEWSWIRE) --...
Hospital at Home Program Helping Cancer Patients and Their Families With Medical and Financial Support Services
June 29, 2022 16:00 ET
|
Hospital At Home
CALGARY, Alberta, June 29, 2022 (GLOBE NEWSWIRE) -- As a competitive dancer and avid horseback rider, Lauren Gamble's life changed completely on Aug. 13, 2021. Lauren received an osteosarcoma...
Invectys appoints Timothy Papp as its Chief Financial Officer
May 12, 2022 10:00 ET
|
Invectys, Inc.
Houston, Texas, USA, May 12, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet...
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board
March 09, 2022 10:00 ET
|
Invectys, Inc.
Houston, Texas, USA, March 09, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to...
NHS Cancer Alliance Implements Inspirata AI to Improve Clinical Trial Access for South West Patients
February 10, 2022 02:59 ET
|
Inspirata, Inc.
Bristol, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata and the Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance (SWAG)...
INVECTYS INC. TO PARTICIPATE IN THE 2021 H.C. WAINWRIGHT 23rd ANNUAL GLOBAL INVESTMENT CONFERENCE SEPTEMBER 13-15, 2021
September 07, 2021 09:00 ET
|
Invectys, Inc.
Houston, Texas, USA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...